Perampanel is currently being investigated in three global phase III clinical trials.
-
Perampanel is an AMPA-type glutamate receptor antagonist. -
AMPA receptors play a key role in causing several neurodegenerative disorders. -
Perampanel is currently being investigated in three global phase III clinical...